Evidence map›Paper›PMID 41644950›Full record

ArticleNature communications2026

A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses.

Abigail E Powell, Hannah Caruso, Soyoon Park, Jui-Lin Chen, Jessica O'Rear, Brian J Ferrer, Daniel J Stieh, Adam M Weiss, David M Belnap, Audrey Walker and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Abigail E PowellVaccine Company, Inc., South San Francisco, CA, USA. apowell@vax.co.ORCID http://orcid.org/0000-0001-6408-9495
Hannah CarusoVaccine Company, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0009-0001-9625-9986
Soyoon ParkVaccine Company, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7399-411X
Jui-Lin ChenVaccine Company, Inc., South San Francisco, CA, USA.
Jessica O'RearVaccine Company, Inc., South San Francisco, CA, USA.
Brian J FerrerVaccine Company, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0500-146X
Daniel J StiehVaccine Company, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0009-0003-8523-1528
Adam M WeissVaccine Company, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4972-1402
David M BelnapSchool of Biological Sciences and Department of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-0619-7487
Audrey WalkerDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Anneliese BrueningDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Airn HartwigDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Kaitlin R SprouseDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0007-2226
Amin AddetiaDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Abeer N AlshukairiCollege of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia.
Vida AhyongVaccine Company, Inc., South San Francisco, CA, USA.
Cristy S DoughertyVaccine Company, Inc., South San Francisco, CA, USA.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6019-8675
Richard BowenDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.ORCID http://orcid.org/0000-0002-7576-2881
Julie E LedgerwoodVaccine Company, Inc., South San Francisco, CA, USA.
Michael S KayVaccine Company, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3186-9684
Payton A-B WeidenbacherVaccine Company, Inc., South San Francisco, CA, USA.
Brad A PalanskiVaccine Company, Inc., South San Francisco, CA, USA.

Funding

Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3M
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) DP1AI158186Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) P01AI167966NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966
6 · The paper itself

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) was identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and considerable pandemic potential, a safe and efficacious vaccine has not been developed. Here we report the design, characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust MERS-CoV pseudovirus and authentic virus neutralizing antibody titers in BALB/c mice. Immunization of male non-human primates (NHPs) with one dose of Alhydrogel-adjuvanted vaccine elicited a > 10

Indexed as

Antibodies, NeutralizingCoronavirus InfectionsFerritinsMiddle East Respiratory Syndrome CoronavirusNanoparticlesSpike Glycoprotein, CoronavirusViral VaccinesAnimalsAntibodies, ViralCross ReactionsDipeptidyl Peptidase 4FemaleHumansMaleMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralDipeptidyl Peptidase 4DPP4 protein, humanFerritinsNanovaccinesProtein Subunit VaccinesSpike Glycoprotein, CoronavirusViral Vaccines

Identifiers

PMID41644950
PMCPMC12913901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.